Scarica l'app Stockscreener
97.08
1.55%
1.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
How Incyte’s (INCY) Opzelura Data and Edison AI Deal Could Reframe Its Risk Profile - simplywall.st
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Grants Equity Awards to New CFO Suketu Upadhyay - MyChesCo
Incyte (INCY) Expands AI Collaboration with Genesis Molecular - GuruFocus
Incyte (INCY) CMO granted 44,124 performance-based shares in Form 4/A - Stock Titan
Incyte (NASDAQ: INCY) awards 31,517 earned performance shares to R&D president - Stock Titan
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
Incyte (INCY) Expands AI Drug Discovery Partnership with Genesis Molecular AI - GuruFocus
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Business Wire
Edison’s AI scientist to be embedded across Incyte discovery and development ops - The Pharma Letter
Incyte stock (US45337C1027): AI partnership and pipeline keep biopharma story moving - AD HOC NEWS
[144] INCYTE CORP SEC Filing - Stock Titan
Incyte Reports Extended Opzelura Eczema Trial Results - MyChesCo
Incyte Stock: Analyst Estimates & Ratings - Barchart.com
Incyte partners with Edison Scientific on AI drug discovery - Investing.com
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development - Business Wire
Incyte Corp stock (US45337C1027): Institutional buying draws fresh attention to the biotech group - AD HOC NEWS
Incyte Corporation $INCY Shares Purchased by Northwestern Mutual Wealth Management Co. - MarketBeat
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build - Yahoo Finance
Baker Bros. Advisors LP Increases Stake in Incyte Corp with Strategic Acquisition - GuruFocus
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies - AD HOC NEWS
Dodge & Cox holds 12.25M Incyte shares (NASDAQ: INCY), a 6.2% stake - Stock Titan
FDA Approves Once-Daily Jakafi XR for Blood Disorders - MyChesCo
Swiss Life Asset Management Ltd Boosts Stake in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Associa - PharmiWeb.com
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress - BioSpace
Incyte to Present Pipeline Strategy at May Investor Conferences - MyChesCo
Baker Brothers and Incyte (INCY): 15,000-share option exercise detailed - Stock Titan
Baker Bros. funds exercise Incyte (NASDAQ: INCY) director stock options - Stock Titan
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24 - Insider Monkey
Incyte Appoints Suketu Upadhyay as Chief Financial Officer - MyChesCo
Incyte Reports Q1 Revenue Growth as Pipeline Advances - MyChesCo
Incyte's (NASDAQ:INCY) Promising Earnings May Rest On Soft Foundations - Yahoo Finance
Mitsubishi UFJ Asset Management Co. Ltd. Increases Stock Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corp. Receives Favorable Valuation Adjustment Amid Strong Financial Performance - Markets Mojo
Does Jakafi XR Approval And Pipeline Progress Change The Bull Case For Incyte (INCY)? - Yahoo Finance
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis - BioSpace
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY Q1 earnings and revenues beat estimates on higher product sales - MSN
Incyte presents 24-week data for ruxolitinib cream in atopic dermatitis - Investing.com
Incyte eczema cream held disease control through 24 weeks - Stock Titan
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 - BioSpace
Incyte (NASDAQ: INCY) grants CFO RSUs, options and performance shares - Stock Titan
MacroGenics and Sagard to expand Zynyz royalty purchase agreement - The Pharma Letter
Here's Why Incyte (INCY) is a Strong Growth Stock - Yahoo Finance
Danske Bank A S Boosts Stake in Incyte Corporation $INCY - MarketBeat
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions - Barchart.com
Incyte Corp. Receives Positive Valuation Adjustment Amid Strong Financial Performance - Markets Mojo
Incyte (INCY) Receives FDA Orphan Designation for Pancreatic Can - GuruFocus
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $135 - GuruFocus
Incyte (INCY) Partners with MacroGenics in Expanded Royalty Agre - GuruFocus
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
2.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):